Pivotal-SUNFISH study of Risdiplam (RG7916) continues to show significant improvement in patients with type 2/3 spinal muscular atrophy

Roche’s risdiplam meets primary endpoint in pivotal SUNFISH trial in people with type 2 or 3 spinal muscular atrophy

Study demonstrated statistically significant improvements in the overall study population with Type 2 or 3 SMA
No treatment related safety findings leading to withdrawal seen in any risdiplam trial to date
Data will be shared with health authorities globally, including the U.S. Food and Drug Administration (FDA)


Clinical Trail
NCT02908685

Roche presents data from the risdiplam pivotal FIREFISH & SUNFISH studies in SMA Typ I-III at the 2019 AAN

Publisert av

Liz

Until those day, was my kiss of death been stronger than those of the devil. I like to ride through hellfire with him ,when I come out victorious afterwards. I'm strong and proud rheumatoid arthritis warrior Följ mig, tack! Liz - Fotoblogg Spelblogg

Ein tanke om “Pivotal-SUNFISH study of Risdiplam (RG7916) continues to show significant improvement in patients with type 2/3 spinal muscular atrophy”

Innlegget er stengt for innspel.